相关实验视频

Updated: Jun 18, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

在二线先进结肠直肠癌治疗中使用拉穆西鲁马布:关于治疗结果和肝脏侧侧侧侧侧血小板聚合的研究

Keisuke Kimura¹, Yosuke Katata², Yuzo Umeda¹

¹Department of Gastroenterological Surgery, Okayama University Hospital, Okayama 700-8558, Japan.

Oncology letters

|July 31, 2024

概括

拉慕西鲁马布 (RAM) 与化疗相结合显示,作为肝转移的晚期结直肠癌的二线治疗方法,有望改善存活率. 与bevacizumab相比,RAM在血小板聚合上表现出明显的影响.

科学领域:

医学瘤学医学瘤学
胃肠病学胃肠病学
药理学药理学是指药理学的学科.

背景情况:

晚期结直肠癌 (CRC) 经常出现肝转移 (LMs),需要有效的二线或救援治疗策略.
抗血管性疗法,包括拉穆西鲁马布 (RAM) 和贝瓦西祖马布 (BEV),用于治疗CRC,但它们对LM和相关生物标记物的比较作用需要进一步阐明.

研究的目的:

为了研究拉穆西鲁马布 (RAM) 加上叶酸,甲和氨酸 (FOLFIRI) 作为晚期结直肠癌和肝转移患者的二线或救援治疗的疗效.
为了比较RAM和BEV对进行肝转移手术切除的患者的血小板聚合的影响.

主要方法:

对36名晚期CRC和LM患者的回顾性分析,这些患者接受了RAM加FOLFIRI治疗 (二线或救援).
基于治疗设置 (二线与救援) 的总生存 (OS) 的评估.
对CD42b进行免疫组织化学分析,以评估在RAM (RAM-LM) 或BEV (BEV-LM) 治疗期间手术切除LMs的患者的血小板聚合得分.

主要成果:

接受RAM加FOLFIRI作为二线治疗的患者 (n=21) 与救援环境 (n=15; 8个月) 患者相比,平均寿命 (23个月) 显著更长.
在化疗期间,有14名患者接受了手术切除LMs.
与BEV-LM组相比,RAM-LM组 (3) 的中位数CD42b血小板聚合得分明显高于BEV-LM组 (1),这表明RAM诱导的血小板聚合在肝脏侧侧中比BEV更大.

结论:

拉慕西鲁马布 (RAM) + 福尔菲里 (FOLFIRI) 作为二线治疗使用时,与具有肝转移的晚期结直肠癌的救援设置相比,显示出更高的整体存活率.
与贝瓦西祖马布 (BEV) 相比,RAM治疗与肝脏鼻中明显且可能更大的血小板聚合程度有关.

关键词:

晚期结直肠癌是什么意思肝脏转移的发生.血小板聚合血小板聚合拉穆齐鲁姆巴布拉姆是什么意思

更多相关视频

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...